Trial Profile
Efficacy and safety of daclatasvir and asunaprevir in patients with chronic hepatitis C
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 03 Aug 2019
Price :
$35
*
At a glance
- Drugs Asunaprevir (Primary) ; Daclatasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 21 Mar 2018 Status changed from not yet recruiting to active, no longer recruiting.
- 30 Sep 2014 New trial record